Drug Trial Radar · NCT02325518
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
Last checked: Nov 20, 2026Latest source record: Dec 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Dec 2014
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Alcon, a Novartis CompanyIndustry
- Sponsor type
- Industry
- First posted
- Dec 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.
Conditions
- Open-Angle Glaucoma
- Ocular Hypertension
Interventions
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspensionDrug
Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solutionDrug
Subject's habitual PGA monotherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AMTime frame: Baseline (Day 0), Week 4, Week 8 at 11 AM
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Japan Ltd. for Trial Locations
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.